Hamasy, A.
15  results:
Search for persons X
?
2

Targets for Ibrutinib Beyond B Cell Malignancies:

Berglöf, A. ; Hamasy, A. ; Meinke, S....
Scandinavian Journal of Immunology.  82 (2015)  3 - p. 208-217 , 2015
 
?
3

Inhibitors of BTK and ITK: State of the New Drugs for Cance..:

Vargas, L. ; Hamasy, A. ; Nore, B. F..
Scandinavian Journal of Immunology.  78 (2013)  2 - p. 130-139 , 2013
 
?
 
?
7

Targets for Ibrutinib Beyond B Cell Malignancies:

Berglöf, A ; Hamasy, A ; Meinke, S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347933/.  , 2015
 
?
12

Eleven percent intact PGM3 in a severely immunodeficient pa..:

Karin E. Lundin ; Qing Wang ; Abdulrahman Hamasy...
http://link.springer.com/article/10.1186/s12887-018-1258-9.  , 2018
 
?
13

Effects of mutations in lymphoid malignancy and immunodefic..:

Hamasy, Abdulrahman M
I. Abdulrahman Hamasy, Qing Wang, K. Emelie M. Blomberg, Dara K. Mohammad, Liang Yu, Mauno Vihinen, Anna Berglöf, and C. I. Edvard Smith. Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia 2017; 31, 177-185. ::doi::10.1038/leu.2016.153 ::pmid::27282255.  , 2017
 
?
14

Implementasi Model Tikrar dalam Menghafal Al Qur'an di Asra..:

Arvaddin Hamasy Al Qosam
https://ejournal.stitpn.ac.id/index.php/palapa/article/view/3880.  , 2023
 
?
15

Implementasi Model Tikrar dalam Menghafal Al Qur'an di Asra..:

Al Qosam, Arvaddin Hamasy
https://ejournal.stitpn.ac.id/index.php/palapa/article/view/3880/1889.  , 2023
 
1-15